SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Company downsizing, staff reduction and layoffs. Employee dismissal, firing and unemployment. Business concept.
Layoffs
Nxera’s Quest for Profitability Claims 15% of Workforce
Nxera, which formerly went by Sosei, will also reprioritize its pipeline to focus on obesity, metabolic and endocrine diseases.
November 18, 2025
 · 
2 min read
 · 
Tristan Manalac
Red rocket with clouds rising up as metaphor for business and financial growth, Success and financial developing, Business growth concept, paper cut style.
Stomach cancer
Jazz, Zymeworks Bispecific Achieves ‘Practice-Changing’ Results in Stomach Cancer Study
With positive data from the Phase III HERIZON-GEA-01 study, Zymeworks and Jazz Pharmaceuticals will file an approval application for Ziihera in the first half of 2026 for the treatment of gastroesophageal adenocarcinoma.
November 18, 2025
 · 
2 min read
 · 
Tristan Manalac
Concept of market share. stock photo
Drug pricing
Before GLP-1s, a Great Pricing Battle Played Out in Hep C Market
The introduction of AbbVie’s hepatitis C drugs in 2014 forced Gilead’s hand in the fight for market dominance in hepatitis C. A similar dynamic is now playing out between Eli Lilly and Novo Nordisk in the obesity space, with some key differences.
November 18, 2025
 · 
7 min read
 · 
Annalee Armstrong
3d rendering of Radiopharmaceuticals, these are radioactive medications or radioisotopes. These medications can be delivered orally in pill form.
Manufacturing
Surge in Radiopharmaceutical R&D Puts Pressure on Unique Supply Chain
The industry’s ability to generate a return on billions of dollars of investment rests on a heavily regulated supply chain defined by time-pressured logistics.
November 18, 2025
 · 
4 min read
 · 
Nick Paul Taylor
Johnson and Johnson sign
Mergers & acquisitions
J&J, Aiming for $50B in Cancer Sales, Buys Halda for $3B in Cash
Halda Therapeutics is developing oral assets for prostate and lung cancer. The deal comes after Johnson & Johnson set an ambitious goal for its oncology sales by 2030.
November 17, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Trendy halftone collage. Concept of contracting, negotiation, contracting, favorable terms. Trendy modern retro illustration on business theme. Concept of teamwork. Vector illustration
Collaboration
Lilly Bets More Than $2.6B for South Korea Biotech’s Bispecific Antibody Platform
The companies have yet to disclose how many programs they plan to collaborate on or what indications they will prioritize.
November 17, 2025
 · 
2 min read
 · 
Tristan Manalac
Courtesy of Sarepta Therapeutics
Regulatory
FDA Imposes Boxed Warning, Narrows Patient Pool for Sarepta’s Duchenne Gene Therapy Elevidys
Sarepta must also run a post-marketing study for Elevidys to better assess the risk of serious liver injury in patients dosed with the gene therapy.
November 17, 2025
 · 
1 min read
 · 
Tristan Manalac
Robotic claw clutching a money stock illustration
Funding
Artios Pushes Cancer Pipeline Forward With $115M Series D
Artios Pharma is working on a pipeline of oncology assets, led by alnodesertib, currently being tested for second-line pancreatic cancer and third-line colorectal cancer.
November 17, 2025
 · 
1 min read
 · 
Tristan Manalac
Group Of Employees Being Fired By Their Company.
Layoffs
Sensei Down to a Handful of Employees to Wrap Up Development Activities
Aside from announcing layoffs, Sensei has decided to terminate its R&D work. The biotech has $25 million on hand, and continues to evaluate its strategic alternatives.
November 17, 2025
 · 
2 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS